Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T17:14:23.300Z.
Calculation as of: 2026-10-06T17:14:23.300Z.
Quote observation: 2026-10-06T17:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 789431897149b7eb66dfe5c794b774a541b173055368acfdd0e045abcb2ddd87
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$261.08M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.32M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.09M
EV/FCF Ratio
432.37x
TTM Avg
210.95x
3Y Avg
227.91x
5Y Avg
182.13x
Market Cap
$264.73M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.36M
EV/FCF Ratio
N/A
TTM Avg
48.59x
3Y Avg
48.59x
5Y Avg
48.59x
Market Cap
$265.36M
EV/FCF Ratio
N/A
TTM Avg
0.65x
3Y Avg
2.46x
5Y Avg
493.92x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palisade Bio, Inc. (PALI) | $261.24M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $261.08M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $259.01M | N/A | 4.58x | 4.76x | 4.76x |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.32M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.09M | 432.37x | 210.95x | 227.91x | 182.13x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | N/A | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $257.49M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.36M | N/A | 48.59x | 48.59x | 48.59x |
| OraSure Technologies, Inc. (OSUR)vs › | $265.36M | N/A | 0.65x | 2.46x | 493.92x |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.00M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
